Literature DB >> 28681504

Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?

Rashi Minocha1,2, Diona L Damian1,2,3, Gary M Halliday1,2.   

Abstract

Ultraviolet radiation (UVR) causes DNA damage in melanocytes by producing photolesions such as cyclobutane pyrimidine dimers and 8-oxo-7-hydrodeoxyguanosine. The production of reactive oxygen species by UVR also induces inflammatory cytokines that, together with the inherent immunosuppressive properties of UVR, propagate carcinogenesis. Nicotinamide (Vitamin B3 ) enhances DNA repair, modulates the inflammatory environment produced by UVR, and reduces UV-induced immunosuppression. As nicotinamide reduces the incidence of actinic keratoses and nonmelanoma skin cancers in high-risk individuals and enhances repair of DNA damage in melanocytes, it is a promising agent for the chemoprevention of melanoma in high-risk populations.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  niacinamide; nicotinamide; skin cancer

Mesh:

Substances:

Year:  2017        PMID: 28681504     DOI: 10.1111/phpp.12328

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  8 in total

Review 1.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

Review 2.  Effects of Non-Opioid Analgesics on the Cell Membrane of Skin and Gastrointestinal Cancers.

Authors:  Natalia Janicka; Agnieszka Sałek; Magdalena Sawińska; Ernest Kuchar; Anna Wiela-Hojeńska; Katarzyna Karłowicz-Bodalska
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

Review 3.  Oral nicotinamide for non-melanoma skin cancers: A review.

Authors:  Samantha Vicki Hunt; Aaron Jamison; Raman Malhotra
Journal:  Eye (Lond)       Date:  2022-03-28       Impact factor: 4.456

4.  Sam68 is required for the growth and survival of nonmelanoma skin cancer.

Authors:  Kai Fu; Xin Sun; Xue Xia; Ryan P Hobbs; Yajuan Guo; Pierre A Coulombe; Fengyi Wan
Journal:  Cancer Med       Date:  2019-08-22       Impact factor: 4.452

Review 5.  Updates on the Management of Non-Melanoma Skin Cancer (NMSC).

Authors:  Artur Fahradyan; Anna C Howell; Erik M Wolfswinkel; Michaela Tsuha; Parthiv Sheth; Alex K Wong
Journal:  Healthcare (Basel)       Date:  2017-11-01

Review 6.  The Role of Nicotinamide in Cancer Chemoprevention and Therapy.

Authors:  Ilias P Nikas; Stavroula A Paschou; Han Suk Ryu
Journal:  Biomolecules       Date:  2020-03-20

7.  Nicotinamide inhibits melanoma in vitro and in vivo.

Authors:  Francesca Scatozza; Federica Moschella; Daniela D'Arcangelo; Stefania Rossi; Claudio Tabolacci; Claudia Giampietri; Enrico Proietti; Francesco Facchiano; Antonio Facchiano
Journal:  J Exp Clin Cancer Res       Date:  2020-10-07

Review 8.  NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation.

Authors:  Evan L Carpenter; Alyssa L Becker; Arup K Indra
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.